House legislation to renew the US Food and Drug Administration’s user fee programs would undo negative court rulings against the agency and reinstate its policies on orphan drug exclusivity and the designation of contrast agents as drugs.
The House user fee bill released by the Democratic and Republican leadership of the House Energy and Commerce Committee on...







